63 results about "SUBCUTANEOUS TUMOR" patented technology

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The present invention relates to the field of biomedicine technology, and specifically discloses an anti-tumor antigen BAP31 monoclonal antibody, a Cy5-BAP31 directly labeled monoclonal antibody and its application. The monoclonal antibody includes a heavy chain variable region and a light chain variable region. The nucleotide sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.3. The nucleotide sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.2, and its amino acid sequence is shown in SEQ ID NO.4. The anti-BAP31 monoclonal antibody provided by the present invention can specifically recognize the BAP31 molecule, inhibit the subcutaneous tumor formation ability and in vivo metastasis ability of liver cancer cells, and significantly prolong the survival of tumor-bearing nude mice.

Phytol (PHY) is a metabolite of plant chlorophyll, is wide in source and is a chain-like diterpenoid substance consisting of four isoprene units, and the phytol ingested by animals is subjected to oxidative metabolism in vivo, so that not only can energy be provided for the animals, but also the growth of the animals can be promoted, and the growth of the animals can be promoted. Moreover, the phytol and the phytanic acid metabolite of the phytol can also be used as signal molecules to participate in glycolipid metabolism and adipocyte differentiation regulation processes, but people cannot directly take the phytol and the phytanic acid from the nature. The effect of phytol in the generation and development of tumors still has huge unknown property. According to the research, the influence of the phytol and the derivative thereof on the growth of colon cancer, breast cancer and melanoma is detected through an in-vitro experiment CCK-8 (Cell Count Kit 8) and an in-vivo experiment such as a mouse subcutaneous tumor model, and the phytol and the derivative thereof are found to be capable of remarkably inhibiting the growth of colon cancer, breast cancer and melanoma and have no obvious toxic and side effects on heart, liver and kidney functions.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

The application discloses a nano-antibody (also known as single-domain antibody) conjugated photosensitizer targeting HER2, a preparation method of the photosensitizer and application of the photosensitizer in tumor photodynamic therapy. The photosensitizer is shown in a general formula (I). In the photosensitizer, the nano-antibody (N HER2 ) serving as a targeting ligand is connected with a photosensitive moiety (PS) through a catalytic reaction mediated by a transglutaminase (MTGase). Research finds that the anti-HER2 nano-antibody conjugated photosensitizer molecule has good cell killing selectivity and tumor enrichment capacity, and can remove a subcutaneous tumor of a mouse with high HER2 expression in one administration. HER2 -PEG 1K -PS (I).

The invention belongs to the technical field of tumor vaccine development, and particularly relates to a tumor cell vaccine of gene knockout MSH2 as well as a preparation method and application of the tumor cell vaccine. Aiming at the problems that the immunogenicity of pMMR tumor cells is low and the tumor cell vaccine prepared from the pMMR tumor cells is difficult to activate an organism to generate effective anti-tumor immunity, the invention provides a cell vaccine of gene knockout MSH2 as well as a preparation method and application of the cell vaccine. The invention discovers that the immunotherapy effect of the tumor cell vaccine can be improved by knocking out the MSH2 for the first time, and proves that the MSH2 can be used as a new transformation target of the tumor cell vaccine. The vaccine is prepared from MSH2 gene knockout tumor cells through irradiation inactivation, it is found that the vaccine can remarkably inhibit growth of far-end subcutaneous tumors and AOM + DSS induced primary colorectal cancer tumors, meanwhile, long-term broad-spectrum anti-tumor immune memory can be induced, and growth of heterogeneous tumor cells is effectively inhibited. In conclusion, the invention has potential significance in clinical application of broad-spectrum tumor cell vaccines.

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

The application provides a kind of intracellular near-infrared light catalysis nano-assembly and preparation method and application, the nano-assembly of the application involves three components, one is the photocatalyst with near-infrared absorption, simultaneously as photothermal reagent, two is NO release base element, three is amphiphilic block copolymer polyethylene glycol block polycaprolactone.By fast nano precipitation method, amphiphilic block copolymer is self-assembled in aqueous solution to load photocatalyst and NO release base element, obtain nano-assembly, the photocatalyst molecule in the nano-assembly can be used as photo-oxidation and reduction catalyst under light condition to activate NO donor molecule to release NO, can also consume intracellular NADH, can also produce heat, can effectively kill triple-negative breast cancer tumor cells, and effectively inhibit tumor growth in mouse subcutaneous tumor model.

The invention discloses a saikoside D self-assembled nano-drug as well as a preparation method and application thereof, saikoside D is self-assembled to form the saikoside D nano-drug (SSD-NPs), and the prepared SSD-NPs has remarkable anti-cancer activity. An in-vitro experiment shows that the SSD-NPs can be used for remarkably inhibiting the activity of HCT-116 and HT-29 colon cancer cells. In addition, the SSD-NPs can also inhibit the cell activity of the hepatoma carcinoma cell Hepg2. Then, an HCT-116 colorectal cancer cell line is taken as an example, the anticancer efficacy of the SSD-NPs is verified in a subcutaneous tumor-bearing mouse model, and the SSD-NPs shows a remarkable anti-colorectal cancer effect in the aspect of improving the size and volume of a subcutaneous tumor-bearing of a CRC mouse. Therefore, the saikoside D nano-drug (SSD-NPs) provided by the invention provides a new candidate compound for cancer treatment.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses a human small cell lung cancer cell line and application thereof, the human small cell lung cancer cell line is preserved in China Center for Type Culture Collection, and the preservation number of the human small cell lung cancer cell line is CCTCC NO: C2024364. The human small cell lung cancer cell line is stable in character and can be stably passaged. The human small cell lung cancer cell line highly retains genetic characteristics and biological behaviors of tumor cells of a patient, the subcutaneous tumor formation rate reaches 100%, and the human small cell lung cancer cell line is suitable for constructing animal models and researching and developing therapeutic drugs and diagnostic reagents and can be used for researching occurrence, development, metastasis and drug resistance mechanisms of small cell lung cancer.

The invention relates to the technical field of medicines, in particular to application of a CD74 gene as a molecular marker in preparation of a bladder cancer immunotherapy curative effect prediction reagent. A mouse bladder cancer subcutaneous tumor model shows that the CD74 inhibits the occurrence and development of the bladder cancer, a bladder cancer patient with high expression of the CD74 has better response to immunotherapy, and it is indicated that the CD74 inhibits the occurrence and development of the bladder cancer and serves as a bladder cancer immunotherapy marker.

The invention discloses a construction method of a humanized diffuse malignant peritoneal mesothelioma mouse model, the mouse model obtained by the construction method and application of the mouse model. The construction method comprises the following steps: constructing a DMPM subcutaneous tumor NOG mouse model by utilizing tumor blocks from human malignant peritoneal mesothelioma; the method comprises the following steps: constructing a huDMPM PBMC-NOG-dko mouse model by utilizing a tumor tissue from a DMPM subcutaneous tumor NOG mouse model; the obtained humanized diffuse malignant peritoneal mesothelioma mouse model completely retains histopathologic characteristics and molecular phenotypes of primary tumors, has a humanized immune system, and can successfully reproduce tumor-immune system interaction characteristics. The method can be used for simulating a tumor microenvironment regulation mechanism of the DMPM, evaluating drugs or therapy of the DMPM and the like.

The invention discloses an imaging window device applied to subcutaneous tumors, and belongs to the technical field of medical apparatuses and instruments. By designing the subcutaneous window comprising the imaging observation ring and the window fixing frame arranged outside the imaging observation ring in a sleeving mode, the weight of the dorsal ridge window is greatly reduced, the burden of a mouse is relieved, and great influences on physiological activities of the mouse can be effectively avoided. By arranging the fixing support detachably connected with the subcutaneous window, the subcutaneous window is fixed in the imaging platform in the imaging process, imaging artifacts caused by respiratory movement of a mouse are reduced, long-time positioning imaging can be achieved, and the imaging effect is better. The subcutaneous window is made of titanium alloy, good biocompatibility is guaranteed, long-term change of skin defect or subcutaneous tumor models can be observed through the window for a long time, blood supply cannot be damaged, a part of soft sponge can be attached to the imaging face of the window, the situation that the skin is prone to necrosis during suturing is avoided, and the real microenvironment is reflected more truly.

The invention belongs to the technical field of nano biomedicine, and particularly discloses a preparation method of a galangin-loaded bionic nano dendritic cell (DCs) vaccine and application of the galangin-loaded bionic nano dendritic cell (DCs) vaccine in ovarian cancer treatment. The inner core of the vaccine is galangin (GA)-loaded polylactic acid-glycolic acid copolymer (PLGA) nanoparticles, and the shell of the vaccine is formed by coating a DCs film carrying tumor antigens. The nano DC vaccine retains the antigen presentation function of natural DCs, and the GA loaded on the nano DC vaccine can induce tumor cells to generate immunogenic cell death. By means of the design, the vaccine can efficiently load specific tumor-associated antigens, and the homing capacity of the vaccine to lymph nodes and tumor microenvironments is remarkably enhanced. Experiments show that GA-NPs (at) DCV is used for treating subcutaneous tumor and in-situ ovarian cancer mouse models.

The invention belongs to the field of antitumor drugs, and particularly relates to a targeted 4-1BB aptamer and application of the targeted 4-1BB aptamer in preparation of antitumor drugs. A target 4-1BB nucleic acid aptamer is obtained through screening, the sequence of the target 4-1BB nucleic acid aptamer is shown as SEQ ID No.1, and the target 4-1BB nucleic acid aptamer is specifically 5 '-CACGCATAACATGTATGGACTGCTCGGGATTGCGG ATTTACATTCGTTATGCGTG-3', the sequence of the target 4-1BB nucleic acid aptamer is shown as SEQ ID No.1, and the sequence of the target 4-1BB nucleic acid aptamer is shown as SEQ ID No.1. The nucleic acid aptamer has a good application effect in preparation of anti-tumor drugs. The capacity of the aptamer for inhibiting mouse Hepa1-6 subcutaneous tumor is superior to that of mouse 4-1BB agonist antibody drugs with the same total mass. The obvious hepatotoxicity and visceral toxicity are not found; growth of mouse Hepa1-6 liver in-situ cancer can be inhibited, and the proportion of CD8 + T cells in T cells in the liver can be increased.

This invention discloses a combination drug of Akkermansia and an EET homologue and its uses, relating to the field of biomedical technology. Specifically, the combination drug of this invention comprises: A1) a first active ingredient, the first active ingredient comprising Akkermansia myxophilus; and A2) a second active ingredient, the second active ingredient comprising at least one of 14,15-epoxyeicosatetrienoic acid (14,15-EET) or an isomer of 14,15-epoxyeicosatetrienoic acid, a pharmaceutically acceptable salt, an ester, or a prodrug. The combination drug of this invention exhibits excellent anti-inflammatory and anti-tumor effects in LPS-induced inflammation models and LLC subcutaneous tumor models. The synergistic index SI > 1 calculated using the Bliss independent model indicates a good synergistic effect, and it can be used for the prevention, treatment, and prognostic improvement of non-small cell lung cancer.

The invention relates to the field of biological pharmacy, and discloses an application of an FABP5 protein target inhibitor in preparation of a product for treating cancers, and the inhibitor is apigenin 7-O-malonyl glucoside. The invention provides a novel cancer cell targeting therapeutic drug, the inhibitor inhibits proliferation of renal clear cell adenocarcinoma and subcutaneous tumor-bearing through precise targeting of FABP5 protein and can be applied to preparation of anti-renal clear cell adenocarcinoma and subcutaneous tumor-bearing drugs, and apigenin 7-O-malonyl glucoside can be used in combination with a PD-1 monoclonal antibody, so that the treatment effect is good. The inhibition effect is better, and a new treatment scheme is provided for the treatment of the kidney cancer.

The invention relates to a compound and a preparation method thereof, a modular polypeptide nano vaccine and a preparation method and application thereof, and relates to the field of medicines, and the chemical structural formula of the compound is shown as a formula I. The compound provided by the invention contains an mPEG-PLA structure, a protoporphyrin structure chelated with cobalt ions, a beta-cyclodextrin structure and the like, so that the compound is endowed with excellent binding capacity with polypeptide and excellent loading capacity with an adjuvant, and co-delivery of the polypeptide and the adjuvant is realized. On the basis, the invention also provides a modular polypeptide nano vaccine, which has the characteristics of high polypeptide loading rate, plug and play and the like, can remarkably inhibit tumor growth in a B16 subcutaneous tumor model, provides an efficient and flexible technical platform for prevention of tumors such as melanoma and clinical transformation of polypeptide vaccines, and has wide application prospects.

The invention discloses application of a hydrogel microneedle capable of being implanted into an abdominal cavity in colorectal cancer abdominal wall infiltration focus, and relates to the field of medicine. The traditional Chinese medicine composition is applied to clinical treatment of rectal cancer abdominal wall infiltration lesions, and a mouse subcutaneous tumor model and the abdominal wall infiltration lesions are verified, and the specific application method comprises the following steps that 1, after a mouse is subjected to general anesthesia, the abdomen of the mouse is opened, and the position of the abdominal wall infiltration lesions is detected and determined; step 2, clamping the sterilized micro-needle sheet by using noninvasive forceps and feeding the sterilized micro-needle sheet into an abdominal cavity; 3, attaching the microneedle substrate to the surface of a focus under direct view, and pressing to enable the needle body to penetrate through the peritoneum; and 4, flushing with normal saline to confirm that the microneedle is fixed, withdrawing the instrument, and suturing the incision. The microneedle physically penetrates through the surface layer of the peritoneum, the medicine is directly delivered to the deep layer of an infiltrating focus, the problem of low efficiency caused by the peritoneum barrier in the traditional therapy is solved, and the GelMA / hyaluronic acid hydrogel is gradually swelled and degraded in body fluid, so that collagenase, a macrophage scavenger and an anti-tumor medicine are continuously released, and the local effective concentration can be maintained for more than two weeks.

The invention provides application of a reagent for detecting epigenetic modification H3T3 and application of an epigenetic modification H3T3 inhibitor, and belongs to the technical field of medicines. Different from the fact that H3pT45 is almost not expressed in tumors and normal tissues, H3pT3 is almost not expressed in the normal tissues but is highly expressed in the tumor tissues, so that high expression of H3pT3 in the colorectal cancer can be used as a screening index, the screening accuracy and the early detection rate are remarkably improved, and a new marker is provided for early detection of the colorectal cancer. In addition, the invention also finds that the H3pT3 inhibitor can significantly inhibit proliferation of colorectal cancer cell lines and significantly delay tumor progression in a mouse subcutaneous tumor model, and shows good anti-tumor activity.

The invention discloses a compound for treating osteosarcoma as well as a preparation method and application thereof. The invention belongs to the technical field of biological medicine. The compound is a 13-methyl-palmatine derivative, and has a structure as shown in the following formula. Experiments prove that the compound 13-methyl-palmatine derivative disclosed by the invention can inhibit proliferation, cloning, migration and invasion capabilities of osteosarcoma cells in vitro. An NYG mouse subcutaneous tumor-bearing experiment proves that the traditional Chinese medicine composition can obviously inhibit the growth of osteosarcoma in vivo. Compared with a positive drug (methotrexate intraperitoneal injection), the 13-methyl-palmatine derivative has a more convenient administration mode (intragastric administration), a safer administration dosage and smaller organ and biochemical index damage degree. The invention provides a new technical means for the treatment of osteosarcoma.

This invention discloses an immune cell with enhanced anti-tumor effect, its preparation method, and its application. Experiments using this invention show that... SERTAD1 CD8 gene overexpression + T cells can enhance their function in anti-tumor immunotherapy. SERTAD1 Gene overexpression can downregulate CD8 + The expression of immune checkpoint molecules on T cells upregulates the expression of mRNAs of tumor-killing cytokines. In the MC38-OVA subcutaneous tumor model, Naïve CD8 cells were extracted from OT-I mice. + T cells were infected with a virus to overexpress SERTAD1, followed by adoptive transfer to mice. The results showed that SERTAD1 overexpression enhanced CD8 expression. + T cells kill MC38-OVA cells, inhibit the growth of MC38-OVA tumor cells, and overexpress SERTAD1 CD8. + The tumor volume and weight in the T-cell adoptive group were significantly smaller than those in the control group.

The present invention discloses a target for tumor treatment and efficacy prediction and its application. The target for tumor treatment and efficacy prediction is MDA5, and also provides the application of MDA5 as a target in treating tumors and as a marker for predicting patient prognosis. The invention proves that MDA5 is an important immunomodulatory factor for colorectal cancer, liver cancer cells, etc. In subcutaneous tumor models of colorectal cancer and liver cancer cell lines in mice, knocking out MDA5 can block and inhibit the occurrence and progression of colorectal cancer and liver cancer, and significantly prolong the survival of tumor-bearing mice. At the same time, targeting MDA5 and combining it with chemotherapy or immune checkpoint inhibitors can more effectively treat and eliminate tumors. MDA5 can be used as a biomarker for poor clinical prognosis of various tumors and can be used to predict patient survival. It provides new ideas for clinical tumor treatment and efficacy prediction, and is expected to provide patients with more acceptable and clinically feasible diagnostic and treatment plans.

This invention belongs to the field of biomedical technology, specifically relating to a Pt 2+ - Carbon dot@protoporphyrin sonodynamic drug delivery system, its preparation method and application, by loading Pt onto the surface of carbon dots 2+ Modification layer, to obtain Pt 2+ After carbon dots are formed, protoporphyrin is loaded onto them to obtain a carbon dot core with Pt loaded on the carbon dot surface. 2+ Modification layer, in Pt 2+ A sonodynamic drug delivery system with a protoporphyrin-modified layer loaded on the outside of the modified layer can be used in anti-tumor drugs to screen liver cancer cells and normal cells. It has good biocompatibility and significant in vivo sonodynamic anti-tumor effects. It can promote the generation of reactive oxygen species, target and remain in the subcutaneous tumor site in vivo for a long time, increase the mortality rate of cancer cells, and inhibit tumor growth. In a 3D constructed in vitro hepatocellular tumor microenvironment model, this drug delivery system still has superior sonodynamic therapeutic effects.

The invention discloses a PD-1 / PD-L1 immunotherapy acquired drug-resistant mouse subcutaneous tumor model construction method based on in-vivo multi-dimensional immune landscape evolution, and relates to the field of animal model construction. Comprising the following steps: preparing tumor cells: resuscitating and amplifying an MC38 colonic adenocarcinoma cell strain, and preparing a single-cell suspension; establishing a basic model: inoculating the MC38 single-cell suspension under the skin of a homologous C57BL / 6 mouse, and establishing a tumor-bearing mouse model; drug resistance induction and screening: after the tumor grows to a predetermined volume, applying continuous treatment pressure of an anti-PD-1 or anti-PD-L1 antibody to the tumor-bearing mouse. Firstly, the tumor volume of mice in a treatment group is compared with the average volume of a control group at the same time point, response mice with the tumor volume obviously smaller than that of the control group are screened out, and primary drug-resistant individuals are excluded. Performing dynamic immune monitoring sampling; and processing and analyzing the sample. The preclinical model has the characteristics of repeatability and dynamic monitoring, and overcomes the defects of the existing preclinical model.

The invention relates to a multi-target molecular ligand as well as a preparation method and application thereof. The multi-targeting molecular ligand disclosed by the invention aims at prostate cancer and bone metastasis thereof, and the ligand simultaneously contains a polypeptide chain Glu-urea-Lys (ACUPA) capable of being recognized by a prostate specific membrane antigen (PSMA), is used for targeting diphosphoric acid of hydroxyapatite nanocrystals in bones, and is also combined with an anisidine fragment which is specifically combined with a Sigma-1 receptor. The multi-target molecular ligand can efficiently mark radionuclide and has excellent radiation stability, cell and animal experiments prove that the multi-target molecular ligand can be efficiently taken by PSMA positive prostate cancer RM-1 cells, RM-1 subcutaneous tumor models and RM-1 tibial metastatic tumor models, and can be used for developing diagnosis and treatment of PSMA positive prostate cancer and bone metastasis thereof, and diagnosis and treatment integration is achieved.

The invention belongs to the technical field of biological medicine, and relates to application of H1FX as a therapeutic target and application of three compounds as H1FX inhibitors in preparation of drugs for preventing and / or treating prostatic cancer. Experimental results show that up-regulation of H1FX expression level can promote proliferation of prostate cancer cells, and knock-down of H1FX can inhibit proliferation of prostate cancer cells. H1FX expression up-regulation can significantly promote generation and development of prostate cancer cell line nude mouse subcutaneous tumor formation. Researches show that the three compounds are specifically combined with H1FX, and proliferation of prostate cancer cells and growth of subcutaneous tumors of nude mice with prostate cancer cell strains are inhibited. Therefore, the invention provides a new target for the design of new anti-prostatic cancer drugs, and provides a new thought for the development and preparation of prostatic cancer prevention and / or treatment drugs.